Navigation Links
DO-HEALTH a multi-center clinical trial on healthy ageing achieves first milestone
Date:9/9/2013

Nyon, Switzerland (September 9, 2013) Europe's largest healthy ageing study DO-HEALTH which aims to provide evidence for the safety of three simple preventive interventions: vitamin D, omega-3 fatty acids and a simple home exercise programme, has recruited 532 of its target 2,000 seniors. In Europe, the number of seniors aged 70 and over will increase by 40 per cent in the next 20 years, and those aged 80 and above will more than double. If action to ensure people age healthily is not taken, not only will it impact their quality of life but it will result in a huge economic burden on health systems in the future.

This is the first large European multi-centre clinical trial which seeks to provide evidence for effective, affordable, and well-tolerated strategies that prevent or delay chronic disease at older age and prolong healthy life expectancy. "We are pleased to announce that the DO-HEALTH study is on track and on target in achieving the 25% recruitment milestone," announced Professor Heike Bischoff-Ferrari, Director of the Centre on Aging and Mobility of Zurich University and DO-HEALTH Principal Investigator.

The seven participating DO-HEALTH study centres in Switzerland, Austria, France, Germany, Portugal and Switzerland are recruiting participants who are 70 years or older, mobile and living independently at home, to take part in the three-year study. Five of the centres are above their targets with 26 to 36% of participants already recruited.

As the European population rapidly ages, age-related chronic diseases in seniors have become a central concern. Chronic diseases prevent millions of seniors from leading longer, more active and independent lives while placing a heavy burden on health care systems and society as a whole.

Among the most promising affordable strategies to promote healthy ageing are vitamin D, marine omega-3 fatty acids and physical exercise. However, their individual and combined effects have yet to be confirmed in a large clinical trial. DO-HEALTH will investigate the impact of these simple strategies in the prevention of chronic disease at older age and will study their role in the prevention of fractures and falls, functional decline, high blood pressure, cognitive decline and pain from osteoarthritis.

International Osteoporosis Foundation CEO, Judy Stenmark stated "Chronic diseases are by far the leading cause of mortality in the world, imposing an enormous burden on patients, their families and on society as a whole. With its ageing population, Europe will have to deal with a dramatic increase in chronic diseases in the next decade therefore, studies such as DO-HEALTH are essential in helping us to better understand and control the disease burden."

She continued, "DO-HEALTH is set to make a vital contribution to the development of low-cost, universally accessible strategies in the fight against age-related chronic diseases. IOF congratulates the DO-HEALTH centres for their dedication to this important study."


'/>"/>

Contact: Charanjit K. Jagait
CJagait@iofbonehealth.org
41-229-940-102
International Osteoporosis Foundation
Source:Eurekalert

Related biology news :

1. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
2. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
3. New clinical trial explores novel noninvasive colon cancer screening test
4. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
5. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
6. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
7. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
8. AAO-HNS releases updated Clinical Indicators
9. Sequencing works in clinical setting to help -- finally -- get a diagnosis
10. VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
11. Clinical trials for Alzheimers disease preventative drug to begin early 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... ... August 06, 2018 , ... Passersby can’t help ... Southern Illinois University Edwardsville’s University Park. SIUE students are working the “Feedstock Diversity ... These three feedstocks represent conventional biofuels production, advanced biofuels production and cellulosic biofuels ...
(Date:8/2/2018)... ... August 02, 2018 , ... Dickinson Wright PLLC ... has been named Practice Group Chair for the Pharmaceuticals and Biotechnology group of ... Dickinson Wright’s healthcare and life sciences initiatives, and appreciate the opportunity to integrate ...
(Date:8/1/2018)... ... August 01, 2018 , ... ... release of Limfinity® version 7.1. Limfinity® is the software framework that all of ... new possibilities for both current users and the future of RURO’s laboratory software ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... August 08, 2018 , ... ActX introduces GenoACT(sm), a Genetic ... by a talented scientific team that includes geneticists, PharmD’s, genetic counselors, and physicians ... on the medical impact of a patient’s genetic variants , 2. Educational information ...
(Date:8/9/2018)... KITCHENER, Canada (PRWEB) , ... August 08, 2018 , ... ... global leader in biotechnology and with a team nearly double its’ size from last ... The sleek new OpenSPR turned heads and impressed crowds at a private ...
(Date:8/9/2018)... ... August 09, 2018 , ... Rockland ... and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a peer-reviewed ... was published online on August 9, 2018 and will be printed in the ...
(Date:8/7/2018)... ... August 06, 2018 , ... Slone Partners, ... the placement of Dr. Paul Harney as President, North America at Prescient Healthcare ... and enhancing client satisfaction. He was also named to Prescient’s Board of Directors. ...
Breaking Biology Technology: